Raphi Levy Sells 20,000 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 20,000 shares of Alpha Tau Medical stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $12.00, for a total value of $240,000.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,082,160. This represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Up 4.7%

Shares of DRTS opened at $13.23 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The company has a 50-day simple moving average of $9.75 and a 200-day simple moving average of $7.85. Alpha Tau Medical Ltd. has a 52 week low of $2.87 and a 52 week high of $13.23. The firm has a market capitalization of $1.20 billion, a P/E ratio of -19.75 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). On average, equities research analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DRTS has been the topic of a number of research reports. LADENBURG THALM/SH SH boosted their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Alpha Tau Medical in a research note on Tuesday, June 2nd. Barclays increased their price objective on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Piper Sandler raised their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, May 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $12.60.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of DRTS. Daytona Street Capital LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter valued at $749,000. Apella Capital LLC acquired a new stake in shares of Alpha Tau Medical during the 4th quarter worth about $1,892,000. Renaissance Technologies LLC bought a new position in Alpha Tau Medical during the 1st quarter valued at about $286,000. Bank of America Corp DE lifted its holdings in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.